ClinicalTrials.gg
CompletedNCT00308750Updated May 13, 2021Results posted

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of enzastaurin and pemetrexed in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
49th of 224
218 · median 65
Started
2006
with 24 others
Phase 2
128 of 228
12 open now
Registered
32nd of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 49th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purposes of this study are to determine:

The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.

Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.

Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.

The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.

The relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.

The effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must have been diagnosed with NSCLC.
  • You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period.
  • You must be willing and able to swallow capsules.
  • Your entry labs and medical tests must meet study requirements.
  • You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing.

Exclusion criteria

Exclusion Criteria:

  • You have received radiation within 2 weeks of study enrollment.
  • You have previously received any anti-cancer drug therapy for NSCLC.
  • You have an active infection or other serious condition.
  • You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy.
  • You have recently lost a significant amount of weight.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Enzastaurin/Pemetrexed/Carboplatin

    Drug: enzastaurin · Drug: pemetrexed · Drug: carboplatin

  • Experimental
    Pemetrexed/Carboplatin

    Drug: pemetrexed · Drug: carboplatin

  • Active comparator
    Docetaxel/Carboplatin

    Drug: docetaxel · Drug: carboplatin

Interventions

  • 1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression

    Also known as: LY317615

  • 500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease

    Also known as: LY231514, Alimta

  • 75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease

  • Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression

    Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.

    Time frame: Baseline to measured PD up to 22.3 months

Secondary outcomes

  1. Tumor Biomarkers Associated With Clinical Outcomes

    As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.

    Time frame: Baseline, Cycle 1, Cycle 2 (21-day cycle each), and 30-day post study treatment follow-up

  2. Assessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes

    Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.

    Time frame: Baseline

  3. Number of Participants With Adverse Events (AEs) or Deaths

    Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.

    Time frame: Baseline through study completion up to 6 cycles (21-day cycle each) and 30-day safety follow-up

  4. Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale

    The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to "worst quality of life" to 136 equal to "best quality of life". The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.

    Time frame: Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]

  5. Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale

    The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 "worst quality of life" to 172 "best quality of life". The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.

    Time frame: Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]

  6. Overall Survival (OS)

    OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.

    Time frame: Baseline to date of death from any cause up to 35 months

  7. Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]

    Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: Baseline to measured PD up to 22.3 months

  8. Duration of CR or PR (Duration of Response)

    The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: Date of first response to the date of progression or death due to any cause up to 22.3 months

  9. Time-to-Treatment Failure (TTF)

    TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.

    Time frame: Baseline to stopping treatment up to 14.1 months

07

Results

Posted May 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Started727472
Received at least 1 dose of study drug677270
Completed03423
Not completed724049
Withdrew: Adverse event9913
Withdrew: Withdrawal by subject623
Withdrew: Physician decision343
Withdrew: Sponsor decision100
Withdrew: Disease progression472428
Withdrew: Unrelated complication301
Withdrew: Death101
Withdrew: Protocol violation100
Withdrew: New primary disease identified110

Outcome measures

PrimaryTime to Disease Progression

Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.

Time frame:
Baseline to measured PD up to 22.3 months
Reported as:
Median · months
Time to Disease Progression
monthsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Time to Disease Progression4.6 (3.2 to 6.7)6.0 (4.6 to 6.5)4.1 (2.6 to 6.3)
Statistical analysis
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.40
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.19
SecondaryTumor Biomarkers Associated With Clinical Outcomes

As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.

Time frame:
Baseline, Cycle 1, Cycle 2 (21-day cycle each), and 30-day post study treatment follow-up

No measurements were reported for this outcome.

SecondaryAssessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes

Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.

Time frame:
Baseline

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) or Deaths

Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.

Time frame:
Baseline through study completion up to 6 cycles (21-day cycle each) and 30-day safety follow-up
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) or Deaths
ParticipantsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
AEs637069
SAEs352026
Deaths Due to AEs354
SecondaryChange From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale

The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to "worst quality of life" to 136 equal to "best quality of life". The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.

Time frame:
Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale
units on a scaleEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Cycle 1 (Week 3)-3.98 ± 1.861.12 ± 1.78-3.33 ± 1.88
Cycle 2 (Week 6)-3.25 ± 2.19-1.54 ± 2.08-2.16 ± 2.42
Cycle 3 (Week 9)0.39 ± 2.300.64 ± 2.25-1.93 ± 2.49
Cycle 4 (Week 12)0.31 ± 2.473.54 ± 2.23-0.81 ± 2.50
Cycle 5 (Week 15)1.89 ± 2.95-0.26 ± 2.57-4.69 ± 2.79
Cycle 6 (Week 18)7.38 ± 3.54-0.83 ± 2.843.38 ± 3.54
Statistical analysis
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.96 (P-value is for the change in Total FACT-L at Cycle 1 (Week 3).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.15 (P-value is for the change in Total FACT-L at Cycle 1 (Week 3).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.92 (P-value is for the change in Total FACT-L at Cycle 2 (Week 6).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.97 (P-value is for the change in Total FACT-L at Cycle 2 (Week 6).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.71 (P-value is for the change in Total FACT-L at Cycle 3 (Week 9).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.66 (P-value is for the change in Total FACT-L at Cycle 3 (Week 9).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.93 (P-value is for the change in Total FACT-L at Cycle 4 (Week 12).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.33 (P-value is for the change in Total FACT-L at Cycle 4 (Week 12).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.19 (P-value is for the change in Total FACT-L at Cycle 5 (Week 15).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.40 (P-value is for the change in Total FACT-L at Cycle 5 (Week 15).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.63 (P-value is for the change in Total FACT-L at Cycle 6 (Week 18).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.55 (P-value is for the change in Total FACT-L at Cycle 6 (Week 18).)
SecondaryChange From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale

The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 "worst quality of life" to 172 "best quality of life". The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.

Time frame:
Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale
units on a scaleEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Cycle 1 (Week 3)-3.16 ± 2.20-0.78 ± 2.08-2.17 ± 2.20
Cycle 2 (Week 6)-6.22 ± 2.90-5.66 ± 2.76-3.13 ± 3.16
Cycle 3 (Week 9)-1.89 ± 3.35-1.52 ± 3.32-4.40 ± 3.62
Cycle 4 (Week 12)-2.28 ± 3.65-0.77 ± 3.29-2.58 ± 3.74
Cycle 5 (Week 15)-2.52 ± 3.71-3.11 ± 3.24-7.74 ± 3.51
Cycle 6 (Week 18)2.77 ± 3.93-2.81 ± 3.26-0.34 ± 4.06
Statistical analysis
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.93 (P-value is for the change in Total FACT-Taxane at Cycle 1 (Week 3).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.86 (P-value is for the change in Total FACT-Taxane at Cycle 1 (Week 3).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.69 (P-value is for the change in Total FACT-Taxane at Cycle 2 (Week 6).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.77 (P-value is for the change in Total FACT-Taxane at Cycle 2 (Week 6).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.83 (P-value is for the change in Total FACT-Taxane at Cycle 3 (Week 9).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.78 (P-value is for the change in Total FACT-Taxane at Cycle 3 (Week 9).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 1.00 (P-value is for the change in Total FACT-Taxane at Cycle 4 (Week 12).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.91 (P-value is for the change in Total FACT-Taxane at Cycle 4 (Week 12).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.49 (P-value is for the change in Total FACT-Taxane at Cycle 5 (Week 15).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.53 (P-value is for the change in Total FACT-Taxane at Cycle 5 (Week 15).)
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.80 (P-value is for the change in Total FACT-Taxane at Cycle 6 (Week 18).)
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · ANCOVA · p = 0.85 (P-value is for the change in Total FACT-Taxane at Cycle 6 (Week 18).)
SecondaryOverall Survival (OS)

OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.

Time frame:
Baseline to date of death from any cause up to 35 months
Reported as:
Median · months
Overall Survival (OS)
monthsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Overall Survival (OS)7.2 (5.7 to 11.2)12.7 (9.3 to 17.0)9.2 (5.9 to 10.7)
Statistical analysis
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.87
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.05
SecondaryNumber of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]

Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
Baseline to measured PD up to 22.3 months
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]
ParticipantsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]91619
SecondaryDuration of CR or PR (Duration of Response)

The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
Date of first response to the date of progression or death due to any cause up to 22.3 months
Reported as:
Median · months
Duration of CR or PR (Duration of Response)
monthsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Duration of CR or PR (Duration of Response)7.4 (3.7 to 8.8)9.3 (5.7 to 14.8)5.8 (3.3 to 11.3)
SecondaryTime-to-Treatment Failure (TTF)

TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.

Time frame:
Baseline to stopping treatment up to 14.1 months
Reported as:
Median · months
Time-to-Treatment Failure (TTF)
monthsEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
Time-to-Treatment Failure (TTF)2.6 (1.7 to 3.7)3.8 (2.8 to 5.1)2.6 (1.3 to 3.7)
Statistical analysis
  • Enzastaurin/Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.71
  • Pemetrexed/Carboplatin vs Docetaxel/Carboplatin · Log Rank · p = 0.04

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzastaurin/Pemetrexed/Carboplatin—35/67 (52.2%)63/67 (94%)
Pemetrexed/Carboplatin—20/72 (27.8%)70/72 (97.2%)
Docetaxel/Carboplatin—26/70 (37.1%)69/70 (98.6%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
PneumoniaInfections and infestations7/673/722/70
Febrile neutropeniaBlood and lymphatic system disorders1/671/726/70
Muscular weaknessMusculoskeletal and connective tissue disorders5/670/723/70
DehydrationMetabolism and nutrition disorders4/671/725/70
HaemoglobinInvestigations4/673/722/70
DyspnoeaRespiratory, thoracic and mediastinal disorders4/672/722/70
SepsisInfections and infestations2/670/724/70
ArrhythmiaCardiac disorders3/671/721/70
Chest painGeneral disorders3/670/720/70
Blood potassium decreasedInvestigations3/670/720/70
Most frequent other events
Showing 10 of 60
Most frequent other events
EventEnzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/Carboplatin
HaemoglobinInvestigations40/6753/7234/70
Neutrophil countInvestigations33/6737/7246/70
Platelet countInvestigations37/6743/7218/70
FatigueGeneral disorders28/6739/7235/70
NauseaGastrointestinal disorders34/6732/7224/70
White blood cell countInvestigations23/6729/7221/70
ConstipationGastrointestinal disorders17/6725/7217/70
AlopeciaSkin and subcutaneous tissue disorders4/676/7220/70
DiarrhoeaGastrointestinal disorders18/6710/7219/70
Decreased appetiteMetabolism and nutrition disorders12/6712/7219/70

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Enzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/CarboplatinTotal
Mean65.2 ± 9.864.0 ± 10.064.0 ± 9.164.4 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Enzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/CarboplatinTotal
Female31333094
Male414142124
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Enzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/CarboplatinTotal
African511824
Caucasian626363188
Hispanic5016
Region of Enrollment
Region of Enrollment(Participants)Enzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/CarboplatinTotal
United States727472218
Disease Stage at Study Entry
Disease Stage at Study Entry(Participants)Enzastaurin/Pemetrexed/CarboplatinPemetrexed/CarboplatinDocetaxel/CarboplatinTotal
Stage IIIB65617
Stage IV666966201
08

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Burlington, North Carolina 27215, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chapel Hill, North Carolina 27599, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, South Carolina 29210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77060, United States
09

References and documents

Publications

  • Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, Rousey SR, Choksi JK, Jotte R, Patt DA, Periman PO, Schlossberg HR, Weissman CH, Wang Y, Asmar L, Pritchard S, Bromund J, Peng G, Treat J, Obasaju CK. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):1963-9. doi: 10.1097/JTO.0b013e3181fd42eb. PubMed 21102260 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 11 years 10 months after primary completion. A results delay was requested in May 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2006
First posted
Mar 30, 2006
Start
Mar 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results delay requested
May 27, 2010
Results first posted
May 13, 2021
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00308750
Responsible party
Sponsor
First posted
Mar 30, 2006
Start date
Mar 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
May 13, 2021
Last update
May 13, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzastaurin · Pemetrexed

Start the discussion